Heterogeneity of Non-HLA Antibody Prevalence in Kidney Antibody-mediated Rejection With the Commercial Luminex Assays.

IF 5 2区医学 Q1 IMMUNOLOGY

Transplantation Pub Date : 2025-08-01 Epub Date: 2025-03-25 DOI:10.1097/TP.0000000000005363

Bogdan Obrișcă, Nicolae Leca, Elaine Chou-Wu, Lena Sibulesky, Ramasamy Bakthavatsalam, Catherine E Kling, Rasha Alawieh, Kelly D Smith, Gener Ismail, Idoia Gimferrer

{"title":"Heterogeneity of Non-HLA Antibody Prevalence in Kidney Antibody-mediated Rejection With the Commercial Luminex Assays.","authors":"Bogdan Obrișcă, Nicolae Leca, Elaine Chou-Wu, Lena Sibulesky, Ramasamy Bakthavatsalam, Catherine E Kling, Rasha Alawieh, Kelly D Smith, Gener Ismail, Idoia Gimferrer","doi":"10.1097/TP.0000000000005363","DOIUrl":null,"url":null,"abstract":"Background: The current state of non-HLA antibody testing in antibody-mediated rejection (AMR) remains not standardized and controversial.Methods: We used 2 different commercial solid-phase assays to investigate the presence of non-HLA antibodies in a cohort of kidney transplant recipients stratified according to biopsy-proven AMR and HLA-donor-specific antibody status.Results: Assay 1 and 2 evaluated 60 and 39 different non-HLAs, of which 25 were shared. From the 25 common antigens, only 36% (n = 9) have a moderate correlation ( r ≥ 0.6) in signal intensity. We observed significant heterogeneity in the prevalence of specific non-HLA antibodies detected between assay 1 and 2. Furthermore, the 2 assays showed substantial differences in the quantities, as well as specificities, of the positive non-HLA antibodies in each patient. Overall, the number of patients with positive antibodies that were detected by both assays was relatively low (median, 5 patients [interquartile range, 3-8] and 6 patients [interquartile range, 3-10] for transplant and biopsy samples, respectively, according to different antigens). Additionally, the panel of specific non-HLA antibodies found associated with AMR (and specifically with AMR/HLA donor-specific antibody negative) and graft loss was assay dependent.Conclusions: We have shown that the current non-HLA antibody assays exhibit significant heterogeneity in terms of antibodies identified per patient and in association with rejection and graft loss.","PeriodicalId":23316,"journal":{"name":"Transplantation","volume":" ","pages":"e409-e421"},"PeriodicalIF":5.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/TP.0000000000005363","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The current state of non-HLA antibody testing in antibody-mediated rejection (AMR) remains not standardized and controversial.

Methods: We used 2 different commercial solid-phase assays to investigate the presence of non-HLA antibodies in a cohort of kidney transplant recipients stratified according to biopsy-proven AMR and HLA-donor-specific antibody status.

Results: Assay 1 and 2 evaluated 60 and 39 different non-HLAs, of which 25 were shared. From the 25 common antigens, only 36% (n = 9) have a moderate correlation ( r ≥ 0.6) in signal intensity. We observed significant heterogeneity in the prevalence of specific non-HLA antibodies detected between assay 1 and 2. Furthermore, the 2 assays showed substantial differences in the quantities, as well as specificities, of the positive non-HLA antibodies in each patient. Overall, the number of patients with positive antibodies that were detected by both assays was relatively low (median, 5 patients [interquartile range, 3-8] and 6 patients [interquartile range, 3-10] for transplant and biopsy samples, respectively, according to different antigens). Additionally, the panel of specific non-HLA antibodies found associated with AMR (and specifically with AMR/HLA donor-specific antibody negative) and graft loss was assay dependent.

Conclusions: We have shown that the current non-HLA antibody assays exhibit significant heterogeneity in terms of antibodies identified per patient and in association with rejection and graft loss.

查看原文本刊更多论文

非hla抗体在肾抗体介导的排斥反应中的异质性与商业Luminex测定。

背景：抗体介导的排斥反应（AMR）中非 HLA 抗体检测的现状仍未标准化且存在争议：我们使用了两种不同的商用固相检测方法，根据活检证实的AMR和HLA-供体特异性抗体状态对肾移植受者队列中存在的非HLA抗体进行了调查：检测 1 和检测 2 分别评估了 60 和 39 种不同的非 HLA，其中 25 种是共有的。在这 25 种共有抗原中，只有 36% （n = 9）的信号强度具有中等相关性（r ≥ 0.6）。我们观察到检测 1 和检测 2 中检测到的特异性非 HLA 抗体的流行率存在明显的异质性。此外，这两种检测方法在每个患者的阳性非 HLA 抗体的数量和特异性上都存在很大差异。总体而言，两种检测方法都检测出阳性抗体的患者人数相对较少（根据不同的抗原，移植样本和活检样本的中位数分别为 5 名患者[四分位数间距为 3-8] 和 6 名患者[四分位数间距为 3-10] ）。此外，发现与AMR（特别是与AMR/HLA供体特异性抗体阴性）和移植物丢失相关的特异性非HLA抗体组依赖于检测方法：结论：我们的研究表明，目前的非 HLA 抗体检测方法在每个患者所发现的抗体以及与排斥反应和移植物丢失的相关性方面表现出明显的异质性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation 医学-免疫学

CiteScore

8.50

自引率

11.30%

发文量

1906

审稿时长

1 months

期刊介绍： The official journal of The Transplantation Society, and the International Liver Transplantation Society, Transplantation is published monthly and is the most cited and influential journal in the field, with more than 25,000 citations per year. Transplantation has been the trusted source for extensive and timely coverage of the most important advances in transplantation for over 50 years. The Editors and Editorial Board are an international group of research and clinical leaders that includes many pioneers of the field, representing a diverse range of areas of expertise. This capable editorial team provides thoughtful and thorough peer review, and delivers rapid, careful and insightful editorial evaluation of all manuscripts submitted to the journal. Transplantation is committed to rapid review and publication. The journal remains competitive with a time to first decision of fewer than 21 days. Transplantation was the first in the field to offer CME credit to its peer reviewers for reviews completed. The journal publishes original research articles in original clinical science and original basic science. Short reports bring attention to research at the forefront of the field. Other areas covered include cell therapy and islet transplantation, immunobiology and genomics, and xenotransplantation.